Key result
Propranolol remains a valuable antihypertensive agent, particularly in patients with comorbid conditions like coronary artery disease and hyperthyroidism.
Why the study?
Despite newer antihypertensive agents, propranolol continues to play a role in hypertension management, particularly in patients with concomitant cardiovascular conditions.
While superseded by newer agents for uncomplicated hypertension, propranolol remains a valuable therapeutic option for hypertensive patients with specific comorbidities like coronary artery disease or hyperthyroidism.
Answers are grounded in this paper and cite their sources.
Review supports propranolol use in select patients with comorbidities; leaves open need for updated comparative trials.
Propranolol, a non-selective beta-adrenergic receptor antagonist, has long been used in the treatment of hypertension. It lowers blood pressure through several mechanisms, including reducing heart rate, myocardial contractility, and inhibiting renin release. Despite newer antihypertensive agents, propranolol continues to play a role, particularly in patients with concomitant cardiovascular conditions. This review examines its pharmacological mechanisms, clinical effectiveness, side effects, and its ongoing relevance in hypertension management.
No takes yet. Share an insight, caveat, or question.
Nisha Bano (2025) conducted a review in Hypertension. Propranolol was evaluated. Propranolol remains a valuable antihypertensive agent, particularly in patients with comorbid conditions like coronary artery disease and hyperthyroidism.
Synapse has enriched 10 related papers. Consider them for comparative context: